ImmuPharma plc (LON: IMM) is the topic of conversation when Navid Malik Executive Director at The Life Sciences Division joins DirectorsTalk. Navid provides some background to TLSD and it’s interest in ImmuPharma, gives a summary of it’s new note on the company, provides some key points on the longer term potential of Lupuzor, Lupus drugs in the market and key milestones he expects the company to achieve over the next period of reach the target share price of 76p.
About ImmuPharma plc
ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.
Lupuzor™ (also referred to as Forigerimod, or P140) is ImmuPharma’s lead compound and a potential treatment for Lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. Lupuzor™ has a novel mechanism of action aimed at modulating the body’s immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.